NetworkNewsBreaks – Pressure BioSciences Inc. (P
Post# of 1354
(Total Views: 129)
Posted On: 03/04/2019 3:35:04 PM
NetworkNewsBreaks – Pressure BioSciences Inc. (PBIO) Announces Collaboration with The Steinbeis Centre
Pressure BioSciences Inc. (OTCQB: PBIO), a leader in the development and sale of pressure-based instruments and platform technologies for the life sciences and other industries worldwide, today announced its entry into a collaboration with world-renowned German research organization The Steinbeis Centre for Biopolymer Analysis & Biomedical Mass Spectrometry. The collaboration seeks to combine unique capabilities of PBIO’s patented pressure cycling technology (“PCT”) for sample preparation, protein characterization and biotherapeutics quality control with the Steinbeis Centre’s innovative PROTEX-MS instrument for elucidating structural details of antibody interactions to create a novel instrument system designed to accelerate the development of new protein therapeutics and improve existing drug treatments.
“This work has very important clinical applications, as it may help to develop more effective protein drugs with reduced side-effects in cancer, auto-immune, neurodegenerative, and other critical diseases and conditions,” PBIO Chief Commercial Officer Dr. Bradford A. Young stated in the news release. “We are honored that Dr. Przybylski and his team have incorporated our proprietary PCT platform as a critical component of this innovative solution. The results of this collaboration will provide PBI with another valuable and broad application area for our Barocycler instruments, and we anticipate this new instrument system will be of great interest to both current and future customers in the monoclonal antibody therapeutics market, expected to reach $218.97 billion by the end of 2023 (Zion Market Research, 2018).”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Pressure BioSciences Inc. (OTCQB: PBIO), a leader in the development and sale of pressure-based instruments and platform technologies for the life sciences and other industries worldwide, today announced its entry into a collaboration with world-renowned German research organization The Steinbeis Centre for Biopolymer Analysis & Biomedical Mass Spectrometry. The collaboration seeks to combine unique capabilities of PBIO’s patented pressure cycling technology (“PCT”) for sample preparation, protein characterization and biotherapeutics quality control with the Steinbeis Centre’s innovative PROTEX-MS instrument for elucidating structural details of antibody interactions to create a novel instrument system designed to accelerate the development of new protein therapeutics and improve existing drug treatments.
“This work has very important clinical applications, as it may help to develop more effective protein drugs with reduced side-effects in cancer, auto-immune, neurodegenerative, and other critical diseases and conditions,” PBIO Chief Commercial Officer Dr. Bradford A. Young stated in the news release. “We are honored that Dr. Przybylski and his team have incorporated our proprietary PCT platform as a critical component of this innovative solution. The results of this collaboration will provide PBI with another valuable and broad application area for our Barocycler instruments, and we anticipate this new instrument system will be of great interest to both current and future customers in the monoclonal antibody therapeutics market, expected to reach $218.97 billion by the end of 2023 (Zion Market Research, 2018).”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Pressure Biosciences (PBIO) Stock Research Links
Scroll down for more posts ▼